Tumor lysis syndrome

K. Arrambide, R. D. Toto

Research output: Contribution to journalArticle

118 Citations (Scopus)

Abstract

Tumor lysis syndrome is a critical illness characterized by massive tumor cell death leading to severe hyperuricemia, hyperphosphatemia, hyperkalemia, hypocalcemia, and acute renal failure in patients with rapidly growing cancers (especially Burkitt's lymphomas with extensive abdominal bulk). It may be preventable with allopurinol therapy combined with aggressive intravenous fluid therapy aimed at establishing an ongoing alkaline diuresis. In most cases renal failure is completely reversible; however, fatal hyperkalemia and volume overload may develop. Therefore, aggressive management with hemodialysis often is necessary to maintain life support while tumor burden is controlled with cytoreductive therapy. Early recognition and management by a team approach in the intensive care unit where careful monitoring is available serves to forestall severe renal failure, thereby improving short-term prognosis in susceptible patients.

Original languageEnglish (US)
Pages (from-to)273-280
Number of pages8
JournalSeminars in Nephrology
Volume13
Issue number3
StatePublished - 1993

Fingerprint

Tumor Lysis Syndrome
Hyperkalemia
Renal Insufficiency
Hyperphosphatemia
Hyperuricemia
Allopurinol
Burkitt Lymphoma
Hypocalcemia
Fluid Therapy
Diuresis
Tumor Burden
Acute Kidney Injury
Critical Illness
Intensive Care Units
Renal Dialysis
Neoplasms
Cell Death
Therapeutics

ASJC Scopus subject areas

  • Nephrology

Cite this

Arrambide, K., & Toto, R. D. (1993). Tumor lysis syndrome. Seminars in Nephrology, 13(3), 273-280.

Tumor lysis syndrome. / Arrambide, K.; Toto, R. D.

In: Seminars in Nephrology, Vol. 13, No. 3, 1993, p. 273-280.

Research output: Contribution to journalArticle

Arrambide, K & Toto, RD 1993, 'Tumor lysis syndrome', Seminars in Nephrology, vol. 13, no. 3, pp. 273-280.
Arrambide K, Toto RD. Tumor lysis syndrome. Seminars in Nephrology. 1993;13(3):273-280.
Arrambide, K. ; Toto, R. D. / Tumor lysis syndrome. In: Seminars in Nephrology. 1993 ; Vol. 13, No. 3. pp. 273-280.
@article{ac068b4c396e48e9ba4701306b6e7fe4,
title = "Tumor lysis syndrome",
abstract = "Tumor lysis syndrome is a critical illness characterized by massive tumor cell death leading to severe hyperuricemia, hyperphosphatemia, hyperkalemia, hypocalcemia, and acute renal failure in patients with rapidly growing cancers (especially Burkitt's lymphomas with extensive abdominal bulk). It may be preventable with allopurinol therapy combined with aggressive intravenous fluid therapy aimed at establishing an ongoing alkaline diuresis. In most cases renal failure is completely reversible; however, fatal hyperkalemia and volume overload may develop. Therefore, aggressive management with hemodialysis often is necessary to maintain life support while tumor burden is controlled with cytoreductive therapy. Early recognition and management by a team approach in the intensive care unit where careful monitoring is available serves to forestall severe renal failure, thereby improving short-term prognosis in susceptible patients.",
author = "K. Arrambide and Toto, {R. D.}",
year = "1993",
language = "English (US)",
volume = "13",
pages = "273--280",
journal = "Seminars in Nephrology",
issn = "0270-9295",
publisher = "W.B. Saunders Ltd",
number = "3",

}

TY - JOUR

T1 - Tumor lysis syndrome

AU - Arrambide, K.

AU - Toto, R. D.

PY - 1993

Y1 - 1993

N2 - Tumor lysis syndrome is a critical illness characterized by massive tumor cell death leading to severe hyperuricemia, hyperphosphatemia, hyperkalemia, hypocalcemia, and acute renal failure in patients with rapidly growing cancers (especially Burkitt's lymphomas with extensive abdominal bulk). It may be preventable with allopurinol therapy combined with aggressive intravenous fluid therapy aimed at establishing an ongoing alkaline diuresis. In most cases renal failure is completely reversible; however, fatal hyperkalemia and volume overload may develop. Therefore, aggressive management with hemodialysis often is necessary to maintain life support while tumor burden is controlled with cytoreductive therapy. Early recognition and management by a team approach in the intensive care unit where careful monitoring is available serves to forestall severe renal failure, thereby improving short-term prognosis in susceptible patients.

AB - Tumor lysis syndrome is a critical illness characterized by massive tumor cell death leading to severe hyperuricemia, hyperphosphatemia, hyperkalemia, hypocalcemia, and acute renal failure in patients with rapidly growing cancers (especially Burkitt's lymphomas with extensive abdominal bulk). It may be preventable with allopurinol therapy combined with aggressive intravenous fluid therapy aimed at establishing an ongoing alkaline diuresis. In most cases renal failure is completely reversible; however, fatal hyperkalemia and volume overload may develop. Therefore, aggressive management with hemodialysis often is necessary to maintain life support while tumor burden is controlled with cytoreductive therapy. Early recognition and management by a team approach in the intensive care unit where careful monitoring is available serves to forestall severe renal failure, thereby improving short-term prognosis in susceptible patients.

UR - http://www.scopus.com/inward/record.url?scp=0027204757&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027204757&partnerID=8YFLogxK

M3 - Article

VL - 13

SP - 273

EP - 280

JO - Seminars in Nephrology

JF - Seminars in Nephrology

SN - 0270-9295

IS - 3

ER -